Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.

Blood cancer journal - 11 Mar 2016

Bühler A, Wendtner C-M, Kipps T J, Rassenti L, Fraser G A M, Michallet A-S, Hillmen P, Dürig J, Gregory S A, Kalaycio M, Aurran-Schleinitz T, Trentin L, Gribben J G, Chanan-Khan A, Purse B, Zhang J, De Bedout S, Mei J, Hallek M, Stilgenbauer S

Abstract excerpt

Efficacy of lenalidomide was investigated in 103 patients with relapsed/refractory chronic lymphocytic leukemia (CLL) treated on the prospective, multicenter randomized phase-II CLL-009 trial. Interphase cytogenetic and mutational analyses identified TP53 mutations, unmutated IGHV, or del(17p) in 36/96 (37.5%), 68/88 (77.3%) or 22/92 (23.9%) patients. The overall response rate (ORR) was 40.4% (42/104). ORRs were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunoglobulin Heavy Chains
Share to Immunologic Factors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lenalidomide

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Recurrence

Share to Retreatment

Share to Survival Analysis

Share to Thalidomide

Source

Open in PubMed Open full text

Identifiers

PMID: 26967821
DOI: 10.1038/bcj.2016.9
PMCID: PMC4817104

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.PMID 26967821Read ↗

Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide.Semantic proximity Read ↗

An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted TherapySemantic proximity Read ↗

Chronic Lymphocytic Leukemia: Prognostic/Predictive Factors in the Era of Novel DrugsSemantic proximity Read ↗

Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemiaSemantic proximity Read ↗

Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era.Semantic proximity Read ↗

The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatmentSemantic proximity Read ↗

Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.Semantic proximity Read ↗

Recent therapeutic advances in chronic lymphocytic leukemiaSemantic proximity Read ↗

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.Semantic proximity Read ↗

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.Semantic proximity Read ↗

17p deletion in chronic lymphocytic leukemia: risk stratification and therapeutic approach.Semantic proximity Read ↗

Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single centerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.